Title:Recent Advances in the Diagnosis of Alzheimer's Disease: A Brief
Overview of Tau PET Tracers in Nuclear Medicine
Volume: 18
Issue: 1
Author(s): Farahnaz Aghahosseini, Yalda Salehi, Saeed Farzanefar, Mohsen Bakhshi Kashi, Elisabeth Eppard, Hojjat Ahmadzadehfar, Siroos Mirzaei, Nasim Vahidfar*Ayuob Aghanejad*
Affiliation:
- Department of Nuclear Medicine, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, 1419733141,
Iran
- Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences,
Tabriz, Iran
- Department of Nuclear Medicine, Faculty of Medicine, Imam Reza General Hospital, Tabriz University of
Medical Sciences, Tabriz, Iran
Keywords:
PET imaging, Alzheimer's disease, dementia, tau, diagnosis, theranostic, radiopharmaceutical.
Abstract: Dementia (the most common cause of Alzheimer's disease) is defined as a chronic or
progressive syndrome with disturbance of multiple cortical functions, the most important of
them including memory, learning capacity, comprehension, orientation, calculation, language,
and judgement. These cognitive impairments affect the quality of life, behavior, and social relations.
Techniques of nuclear medicine provide feasible ways to record the intracellular alterations
of disease and deficiencies. In these non-invasive manners, the hippocampal-neocortical
disconnection may partly explain the hypo-metabolism incident found in Alzheimer's disease.
Based on this fact, the study of all these mechanisms of action is conceivable and achievable by
radiopharmaceuticals. This review is aimed at the presentation of radiopharmaceuticals that are
developed for the detection of Alzheimer’s disease in preclinical and clinical trials.
